| Literature DB >> 26922892 |
Taimur S Butt1, Irene Koutlakis-Barron2, Suliman AlJumaah2, Sahar AlThawadi3, Saleh AlMofada4.
Abstract
BACKGROUND: Transmission of Middle East respiratory syndrome-coronavirus (MERS-CoV) among health care workers (HCWs) and patients has been documented with mortality rate approximating 36%. We propose advanced infection control measures (A-IC) used in conjunction with basic infection control measures (B-IC) help reduce pathogen transmission. B-IC include standard and transmission-based precautions. A-IC are initiatives implemented within our center to enhance effectiveness of B-IC.Entities:
Keywords: Health care worker; Infection prevention; MERS-CoV; Occupational exposure
Mesh:
Year: 2016 PMID: 26922892 PMCID: PMC7115292 DOI: 10.1016/j.ajic.2016.01.004
Source DB: PubMed Journal: Am J Infect Control ISSN: 0196-6553 Impact factor: 2.918
Basic and advanced infection control measures
| Basic infection control measures | Advanced infection control measures |
|---|---|
Hand hygiene Personal protective equipment for health care workers Protection during aerosol-generating procedures Environment and equipment cleanliness Patient screening, placement, and transportation Duration of transmission-based precautions Management of health care worker exposures Visitor control Availability of essential supplies Basic resources | Interdepartmental collaborative meetings Infection control risk assessment Middle East respiratory syndrome-coronavirus epidemic plan Flagging electronic charts Infection prevention and control team on call Interhospital patient acceptance and transfer criteria Ordering, collection, and transportation of Middle East respiratory syndrome-coronavirus specimens Real-time polymerase chain reaction Middle East respiratory syndrome-coronavirus testing capability Stockpiling of essential supplies High-efficiency particulate-respirator fit testing Advanced airway management Emergency department contingency plan Specific staff education and communication Patient, family, and visitor education, and communication Transparency |
Middle East respiratory syndrome-coronavirus (MERS-CoV) epidemic plan
| Part I |
| Phase 1: Low level of alertness for MERS-CoV epidemic plan: No cases or expected influx of MERS-CoV—usual practice |
| • Process for admission/discharge, inpatient management, and assessment in emergency department per policy |
| • Infection control measures per policy |
| Phase 2: Moderate level of alertness for MERS-CoV—1-2 confirmed cases within the institution |
| • Administration announce escalation of alertness for potential of transmission |
| • Increase stockpiles of essential supplies by 6 times the average monthly usage (ie, surgical and N95 masks, gown, gloves, goggles, and hand hygiene products) |
| • Focused hospitalwide education campaign to improve compliance with infection control measures related to MERS-CoV |
| • Emergency department prescreening for early identification and isolation of flu-like illness ( |
| • Assigned unit with airborne infection isolation rooms for admission and cohort of confirmed MERS-COV cases |
| Phase 3: High level of alertness for MERS-CoV epidemic plan—greater than 3 cases within the institution, outbreak risk, and/or expected influx due to Ministry of Health directive |
| • In addition to phase 2 |
| • Decrease hospital occupancy by 15% |
| • Limit admission of referrals as applicable; that is, refer noncritical patients to other medical centers |
| De-escalation of alertness |
| • Decrease in the number of confirmed MERS-CoV cases within the institution |
| • Ministry of Health situational reports and directive |
| Part II |
| Measures to decrease inpatient occupancy |
| • Daily assessment of service specific bed use by department chairman and case management |
| • Cancellation of elective and nonessential surgeries, procedures, and admissions |
Fig 1Prescreening for flu-like illness in the emergency department. AIIR, airborne infection isolation room; DEM, Department of Emergency Medicine; MERS-CoV, Middle East respiratory syndrome-coronavirus; NPA, nasopharyngeal aspirate; PCR, polymerase chain reaction; PPE, personal protective equipment; SARI, severe acute respiratory illness. *Including hand hygiene, facial protection, gloves with or without gown, and N-95 mask (if fit tested).
Fig 2Education posters/rollups.
Fig 3Test results of the study period beginning July 1, 2013, and ending January 31, 2015.
Patient demographic characteristics
| Case | Age, y | Gender | Comorbidities | Presenting symptoms | Date of admission | Date first sample taken and positive | Date negative or died | Potential HCW exposure days | Outcome | Death attributed to MERS-CoV Yes/No |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | Female | DM/HTN/lymphoma/cardiomyopathy | Respiratory | 24/07/2013 | 15/08/2013 | 28/08/2013 | 33 | Discharged 05/09/2013 | N/A |
| 2 | 52 | Male | Retroperitoneal sarcoma | Respiratory | 24/07/2013 | 27/07/2013 | 08/08/2013 | 16 | Died | Yes |
| 3 | 54 | Male | HTN/DM/ESRD/CAD | Respiratory | 28/07/2013 | 14/08/2013 | 18/08/2013 | 14 | Died | Yes |
| 4 | 50 | Male | DM | Respiratory/ARDS/known MERS-CoV positive | 06/08/2013 | 27/08/2013 | 29/08/2013 | 23 | Discharged 09/09/2013 | N/A |
| 5 | 54 | Female | HTN/treated parotid carcinoma | Respiratory | 24/09/2013 | 24/09/2013 | 06/10/2013 | 13 | Discharged 18/10/2013 | N/A |
| 6 | 73 | Male | DM/HTN/CAD | Respiratory | 12/10/2013 | 15/10/2013 | 08/12/2013 | 57 | Died | Yes |
| 7 | 73 | Male | CKD/HTN/RHD | Respiratory | 12/12/2013 | 12/12/2013 | 18/12/2013 | 7 | Died | Yes |
| 8 | 84 | Male | HTN/right BBB | Respiratory | 01/03/2014 | 10/03/2014 | 23/03/2014 | 24 | Died | Yes |
| 9 | 19 | Male | Nil | Respiratory | 13/03/2014 | 15/03/2014 | 30/03/2014 | 18 | Discharged 02/04/2014 | N/A |
| 10 | 56 | Female | DM/HTN | Respiratory | 02/05/2014 | 03/05/2014 | 05/05/2014 | 4 | Discharged 25/06/2014 | N/A |
| 11 | 49 | Male | HTN/ESRD on PD/HBV | Respiratory | 02/05/2014 | 02/05/2014 | 09/06/2014 | 39 | Discharged 08/07/2014 | N/A |
| 12 | 72 | Male | NHL/HBV/cardiomyopathy | Respiratory | 06/08/2014 | 09/08/2014 | 17/08/2014 | 12 | Died | Yes |
| 13 | 32 | Female | NHL on CTX | Respiratory | 23/12/2014 | 24/12/2014 | 18/01/2015 | 27 | Died | Yes |
| 14 | 52 | Male | DM/HTN/ renal cell Ca | Respiratory | 22/02/2015 | 22/02/2015 | 17/03/2015 | 24 | Died | Yes |
| 15 | 60 | Male | Metastatic pancreatic Ca | Respiratory | 24/02/2015 | 26/02/2015 | 02/03/2015 | 7 | Died | Yes |
| 16 | 64 | Male | Postrenal transplant | Respiratory | 28/02/2015 | 01/03/2015 | 19/03/2015 | 20 | Died | Yes |
ARDS, adult respiratory distress syndrome; BBB, bundle branch block; Ca, cancer; CAD, coronary heart disease; CKD, chronic kidney disease; CTX, chemotherapy; DM, diabetes mellitus; ESRD, end-stage renal disease; HBV, hepatitis B virus; HTN, hypertension; MERS-CoV, Middle East respiratory syndrome-coronavirus; NHL, non-Hodgkin's lymphoma; PD, peritonitis dialysis; RHD, rheumatic heart disease.